I now have comprehensive data from multiple authoritative textbooks with structural diagrams. Let me now write the full, detailed clinical answer.
Penicillins - Complete Guide: Basics to Clinical
1. The Penicillin Nucleus - Understanding the Core Structure
All penicillins are built on 6-aminopenicillanic acid (6-APA), which consists of two fused rings:
- Ring A = Thiazolidine ring
- Ring B = Beta-lactam ring (the pharmacologically active part)
- R group = Side chain that determines spectrum, acid stability, and resistance to beta-lactamases
When penicillinase (beta-lactamase) cleaves the beta-lactam ring at site 1, the product is penicilloic acid - which has no antibacterial activity but IS antigenic (causing allergic reactions). When amidase cleaves at site 2, the free 6-APA nucleus is released.
2. Mechanism of Action
Penicillins are bactericidal (they kill bacteria, not just inhibit them). Here is the step-by-step mechanism:
Step 1 - Target identification:
Bacteria build their cell wall from peptidoglycan, a mesh of sugar chains (NAM-NAG) cross-linked by short peptide bridges.
Step 2 - Enzyme inhibition:
Cross-linking is performed by enzymes called Penicillin-Binding Proteins (PBPs) - specifically transpeptidases. Penicillin's beta-lactam ring mimics the D-Ala-D-Ala terminus of the peptide precursor. It binds irreversibly to the active site of PBPs, blocking transpeptidation.
Step 3 - Cell wall weakening:
Without cross-linking, new peptidoglycan cannot be synthesized. The growing cell wall becomes structurally defective.
Step 4 - Autolysis:
The bacteria's own autolytic enzymes (murein hydrolases) continue degrading old peptidoglycan while new synthesis is blocked. This leads to cell lysis and death.
Key points: Active only against actively dividing bacteria (you need ongoing cell wall synthesis). Completely ineffective against organisms without a cell wall (Mycoplasma, intracellular bacteria, fungi, viruses).
3. Classification of Penicillins
Penicillins fall into five groups based on their antimicrobial spectrum:
| Group | Drugs | Key Feature |
|---|
| 1. Natural Penicillins | Penicillin G, Penicillin V | Gram-positive, narrow spectrum |
| 2. Antistaphylococcal (Penicillinase-resistant) | Nafcillin, Oxacillin, Dicloxacillin, Cloxacillin | Resistant to staph beta-lactamase |
| 3. Aminopenicillins | Ampicillin, Amoxicillin | Extended to some gram-negatives |
| 4. Carboxypenicillins | Ticarcillin (largely discontinued) | Anti-Pseudomonal |
| 5. Ureidopenicillins | Piperacillin | Broadest spectrum, anti-Pseudomonal |
| +BLI combinations | Amoxicillin-clavulanate, Ampicillin-sulbactam, Piperacillin-tazobactam | Overcome beta-lactamase resistance |
4. Group-by-Group Drug Details
GROUP 1 - Natural Penicillins
A. Penicillin G (Benzylpenicillin)
Spectrum:
- Gram-positive cocci: Streptococcus pyogenes (Group A Strep), viridans streptococci, Streptococcus pneumoniae (penicillin-sensitive strains)
- Gram-positive rods: Clostridium spp., Actinomyces israelii, Listeria monocytogenes
- Gram-negative cocci: Neisseria meningitidis (meningococcus - almost always sensitive), some Neisseria gonorrhoeae (most are now resistant)
- Spirochetes: Treponema pallidum (syphilis), Leptospira spp., Borrelia burgdorferi (Lyme)
- Anaerobes (NOT Bacteroides fragilis)
Route: IV or IM only - acid labile, destroyed by stomach acid, cannot be given orally.
Formulations and Doses:
| Formulation | Route | Dose | Duration of Action | Use |
|---|
| Penicillin G aqueous | IV | 2-4 million units q4-6h (up to 24 million units/day for severe infection) | Minutes-hours | Serious/severe infections |
| Penicillin G procaine | IM | 600,000 units IM once or twice daily | 12-24 hours | Moderate infections, outpatient |
| Penicillin G benzathine | IM | 1.2-2.4 million units single dose | 10-21 days | Strep pharyngitis, syphilis prophylaxis |
How benzathine/procaine works: These are repository (depot) formulations. Procaine and benzathine are poorly soluble salts that dissolve slowly at the IM injection site, releasing penicillin G gradually. Benzathine gives detectable levels for up to 3-4 weeks from one injection.
Drug of Choice (DOC) clinical cases:
- Syphilis (all stages): Benzathine Pen G 2.4 million units IM x1 (primary/secondary), x3 weekly doses (latent/tertiary)
- Strep pharyngitis (Group A): Benzathine Pen G 1.2 million units IM x1
- Rheumatic fever prophylaxis: Benzathine Pen G 1.2 million units IM every 3-4 weeks
- Meningococcal meningitis: Penicillin G 4 million units IV q4h x 7-10 days
- Gas gangrene (Clostridium): Penicillin G 3-4 million units IV q4h + surgical debridement
- Leptospirosis (severe): Penicillin G 1.5 million units IV q6h
- Actinomycosis: Penicillin G 10-20 million units/day IV x 4-6 weeks, then oral Pen V
Contraindications/Precautions:
- Allergy to penicillin (anaphylaxis, urticaria, serum sickness) - ABSOLUTE
- Procaine allergy (for procaine Pen G)
- Electrolyte caution: Large IV doses contain sodium or potassium - monitor in renal failure and heart failure
B. Penicillin V (Phenoxymethylpenicillin)
Differs from Pen G: Acid-stable (can be given orally). Produces 2-5x higher plasma levels than oral Pen G. But bioavailability is still modest, requires QID dosing, narrow spectrum - so amoxicillin is often preferred.
Route: Oral only
Dose: 250-500 mg orally every 6 hours (take on empty stomach - food impairs absorption)
Uses:
- Mild streptococcal pharyngitis
- Mild odontogenic (dental) infections
- Step-down therapy after IV penicillin G
- NOT suitable for serious infections
DOC example:
- Mild strep throat in a child (who can swallow pills): Pen V 250 mg QID x 10 days
GROUP 2 - Penicillinase-Resistant (Antistaphylococcal) Penicillins
The isoxazolyl ring (in oxacillin, dicloxacillin, cloxacillin) creates steric hindrance that prevents beta-lactamase from cleaving the beta-lactam ring.
Spectrum:
- S. aureus (MSSA - methicillin-susceptible) - this is their main target
- Streptococci (but less active than Pen G)
- NOT effective against MRSA (different resistance mechanism - altered PBP2a)
- NOT active against gram-negatives, enterococci, Listeria
A. Nafcillin
- Route: IV only (oral absorption erratic)
- Dose: 1-2 g IV every 4-6 hours (total 8-12 g/day for serious infections)
- Unique pharmacology: Hepatic elimination (not renal) - preferred in renal failure
- Uses/DOC: Serious MSSA infections - bacteremia, endocarditis, osteomyelitis, septic arthritis, skin and soft tissue infections, meningitis
Clinical case example: 45-year-old IV drug user presents with fever, new murmur, and echocardiogram showing vegetation on tricuspid valve. Blood cultures grow MSSA. Treatment: Nafcillin 2 g IV q4h x 6 weeks for right-sided endocarditis.
B. Oxacillin
- Route: IV only
- Dose: 1-2 g IV every 4-6 hours
- Eliminated by: Both hepatic and renal routes
- Uses: Same as nafcillin - serious MSSA infections
C. Dicloxacillin
- Route: Oral (acid stable, good bioavailability)
- Dose: 250-500 mg orally every 6 hours (taken 1 hour before meals - food reduces absorption)
- Uses/DOC: Mild-moderate localized MSSA infections - cellulitis, mild skin and soft tissue infections, step-down from IV nafcillin/oxacillin
Clinical case example: Patient is discharged after 5 days of IV nafcillin for MSSA cellulitis. Step-down: Dicloxacillin 500 mg PO q6h x 10 days total.
D. Cloxacillin / Flucloxacillin
- Available in many countries (not US), same spectrum as dicloxacillin
- Flucloxacillin 500 mg QID PO or IV, widely used in UK/Australia for MSSA
Why not use these for MRSA? MRSA has acquired the mecA gene, which encodes an altered PBP called PBP2a with very low affinity for all penicillins (and most beta-lactams). No modification of the R-group overcomes this - hence vancomycin is used for MRSA.
GROUP 3 - Aminopenicillins
An amino group (-NH₂) is added to the R side chain. This allows penetration through the outer membrane of gram-negative bacteria, extending the spectrum. However, these drugs ARE susceptible to beta-lactamases.
Spectrum (compared to Pen G - adds):
- E. coli, Proteus mirabilis, Haemophilus influenzae, Shigella, Salmonella, Enterococcus faecalis
- Still active against Strep, Listeria
- NOT Pseudomonas, Klebsiella, most gram-negative nosocomial pathogens
A. Ampicillin
- Route: IV/IM (oral absorption poor and variable)
- Dose: 1-2 g IV q4-6h for moderate infections; up to 12 g/day for meningitis
- Half-life: ~1 hour; renal excretion (dose adjust in renal failure)
DOC cases:
- Listeria monocytogenes meningitis (especially neonates and immunocompromised/elderly): Ampicillin 2 g IV q4h + gentamicin
- Enterococcal endocarditis: Ampicillin 2 g IV q4h + gentamicin x 4-6 weeks
- Neonatal meningitis (empiric, covers Listeria + GBS + gram-negatives): Ampicillin + cefotaxime
Clinical case example: 70-year-old diabetic with fever and CSF showing gram-positive rods, confirmed as Listeria monocytogenes. Treatment: Ampicillin 2 g IV q4h x 21 days + gentamicin for synergy.
B. Amoxicillin
- Route: Oral only (much better absorbed than ampicillin - 80% vs 40%)
- Dose:
- Standard: 500 mg PO TID or 875 mg PO BID
- High-dose (for drug-resistant Strep pneumoniae): 1 g TID
- H. pylori: 1 g BID (as part of triple/quadruple therapy)
- Food effect: Can be taken with food (unlike most penicillins) - this is clinically useful for compliance
- Same spectrum as ampicillin but oral bioavailability is the key advantage
DOC cases:
- Community-acquired pneumonia (outpatient, mild): Amoxicillin 1 g TID x 5-7 days (adults) or 90 mg/kg/day (children)
- Acute otitis media: Amoxicillin 80-90 mg/kg/day divided BID x 10 days (high dose for penicillin-resistant Strep pneumo)
- Strep pharyngitis (preferred oral agent): Amoxicillin 500 mg BID x 10 days
- H. pylori eradication: Amoxicillin 1 g BID + clarithromycin 500 mg BID + PPI x 14 days
- Lyme disease (early localized): Amoxicillin 500 mg TID x 14-21 days
- Dental infections (mild-moderate): Amoxicillin 500 mg TID x 5-7 days
Clinical case example: 5-year-old with fever, ear pulling, and bulging tympanic membrane (otitis media). First episode, no antibiotics in past month. Treatment: Amoxicillin 90 mg/kg/day in 2 divided doses x 10 days (high dose because up to 40% of Strep pneumoniae has reduced sensitivity).
GROUP 4/5 - Extended-Spectrum: Carboxypenicillins & Ureidopenicillins
Piperacillin (Ureidopenicillin)
This is the clinically relevant member (carbenicillin, ticarcillin largely discontinued in US).
Spectrum: The broadest of all penicillins:
-
All of ampicillin's coverage PLUS
-
Pseudomonas aeruginosa
-
More gram-negatives: E. coli, Klebsiella, Proteus, Enterobacter, many Bacteroides
-
Retains activity against enterococci and Listeria
-
Route: IV only
-
Dose: 3-4 g IV q4-6h (typically given as piperacillin-tazobactam combination - see below)
-
Alone it is susceptible to beta-lactamases, so rarely used without tazobactam
GROUP 6 - Beta-Lactamase Inhibitor Combinations
These add a beta-lactamase inhibitor (BLI) that has weak or no intrinsic antibacterial activity but protects the penicillin from enzymatic destruction. They bind irreversibly to beta-lactamases, acting as "suicide inhibitors."
| Drug | Penicillin | BLI | Route |
|---|
| Amoxicillin-clavulanate (Augmentin) | Amoxicillin | Clavulanic acid | Oral |
| Ampicillin-sulbactam (Unasyn) | Ampicillin | Sulbactam | IV/IM |
| Piperacillin-tazobactam (Pip-Tazo, Zosyn) | Piperacillin | Tazobactam | IV |
| Ticarcillin-clavulanate | Ticarcillin | Clavulanic acid | IV (not available US) |
A. Amoxicillin-Clavulanate (Augmentin)
- Doses:
- Standard: 875/125 mg PO BID
- High-dose: 2000/125 mg (Augmentin XR) BID for resistant Strep pneumo
- Pediatric: 45 mg/kg/day (amoxicillin component) divided BID using 600/42.9 mg/5mL suspension
- Spectrum adds (beyond amoxicillin): Beta-lactamase-producing H. influenzae, Moraxella catarrhalis, S. aureus (MSSA), many gram-negatives
- GI side effects are common - take with food to minimize diarrhea (clavulanate causes GI upset)
DOC cases:
- Acute bacterial sinusitis (first choice): Amox-clav 875/125 mg BID x 5-7 days
- Animal/human bites: Amox-clav 875/125 mg BID x 5 days (covers Pasteurella, oral flora)
- Community-acquired pneumonia in patients with comorbidities: Amox-clav + macrolide
- Acute otitis media, failed first-line amoxicillin: Amox-clav high dose
Clinical case example: 8-year-old with dog bite on hand, moderate depth wound. Treatment: Amoxicillin-clavulanate 45 mg/kg/day BID x 5 days (covers Pasteurella multocida from dog saliva + skin flora).
B. Ampicillin-Sulbactam (Unasyn)
- Dose: 3 g (2 g ampicillin + 1 g sulbactam) IV q6h; adjust for renal failure
- Special feature: Sulbactam itself has intrinsic activity against Acinetobacter baumannii - important in high-dose use for MDR Acinetobacter
- Spectrum: Amoxicillin-clav spectrum but parenteral; covers oral and GI flora well, NOT Pseudomonas
DOC/Common use cases:
- Intra-abdominal infections (mild-moderate): Amp-sulbactam 3 g IV q6h
- Aspiration pneumonia/lung abscess: Amp-sulbactam 3 g IV q6h (covers oral anaerobes)
- Pelvic inflammatory disease: Part of inpatient regimen
- Soft tissue infections with mixed flora
Clinical case example: 55-year-old alcoholic, found obtunded, chest X-ray shows right lower lobe infiltrate with cavitation, sputum has foul odor. Diagnosis: aspiration pneumonia/lung abscess. Treatment: Ampicillin-sulbactam 3 g IV q6h x 4-6 weeks (covers mouth anaerobes including Bacteroides, Peptostreptococcus).
C. Piperacillin-Tazobactam (Pip-Tazo / Zosyn)
- Dose: 3.375 g (3 g pip + 0.375 g tazo) IV q6h standard; 4.5 g q6h or q8h for Pseudomonas; 4.5 g extended infusion over 3-4 hours q8h (pharmacokinetic optimization for serious gram-negative infections)
- Spectrum: The broadest penicillin available: gram-positives, gram-negatives, anaerobes, Pseudomonas. Covers most hospital-acquired pathogens except MRSA, Acinetobacter, ESBL-producers
- Adjust: Renal dosing required (renally cleared); monitor for hypokalemia (nephrotoxicity with vancomycin)
DOC/Common use cases:
- Healthcare-associated pneumonia / ventilator-associated pneumonia (VAP): Pip-Tazo 4.5 g q8h extended infusion
- Febrile neutropenia (empiric): Pip-Tazo 4.5 g q6h as monotherapy
- Intra-abdominal infection (severe/hospital-acquired): Pip-Tazo 3.375 g q6h
- Diabetic foot infection (moderate-severe): Pip-Tazo 4.5 g q8h
- Hospital-acquired urinary tract infection
- Sepsis of unknown source in hospitalized patients
Clinical case example: A 60-year-old on chemotherapy develops fever (38.9°C) and absolute neutrophil count of 200 cells/µL. Diagnosis: Febrile neutropenia. Empiric treatment: Piperacillin-tazobactam 4.5 g IV q6h (or q8h extended infusion) until cultures return or fever resolves and ANC recovers.
5. Pharmacokinetics Summary
| Property | Details |
|---|
| Distribution | Wide - joints, pleura, pericardium, bile |
| Protein binding | Nafcillin highest (>90%) → lower free drug; Pen G, ampicillin lower binding |
| CNS penetration | <1% normal meninges; up to 5% with inflamed meninges |
| Prostate/eye | Poor penetration |
| Elimination | Primarily renal (tubular secretion ~90%, GF ~10%); half-life ~30 min for Pen G |
| Exception | Nafcillin - hepatic elimination (safe in renal failure without dose adjustment) |
| Time-dependent killing | Penicillins are TIME-dependent bactericidals - what matters is the % of time free drug is above MIC (not peak concentration). This is why extended infusions or frequent dosing intervals are used. |
Probenecid: Blocks renal tubular secretion of penicillins → increases and prolongs serum levels. Historically used to boost levels (e.g., in syphilis treatment where benzathine was scarce).
Oral absorption tips:
- Amoxicillin: Take with OR without food
- Dicloxacillin, penicillin V, ampicillin: Take on empty stomach (1 hour before or 2 hours after food)
6. Resistance Mechanisms
There are four ways bacteria resist penicillins:
-
Beta-lactamase production (most common) - enzyme cleaves the beta-lactam ring. Countered by: penicillinase-resistant penicillins (Group 2), or BLI combinations.
-
Altered PBPs (target modification) - MRSA has PBP2a (low affinity for all beta-lactams). Penicillin-resistant Strep pneumoniae has altered PBP2b/2x. Cannot be overcome by any penicillin.
-
Efflux pumps - bacteria pump the drug out (e.g., Pseudomonas). Piperacillin partially overcomes this.
-
Reduced outer membrane permeability - gram-negatives lose porin channels that allow penicillin entry (e.g., Pseudomonas, imipenem-resistant Enterobacter).
7. Adverse Effects
Allergy (most important adverse effect)
| Type | Presentation | Timing | Management |
|---|
| Immediate (Type I, IgE-mediated) | Anaphylaxis, urticaria, angioedema, bronchospasm | Within 1 hour | Stop drug; epinephrine 0.3 mg IM; ICU |
| Accelerated urticarial | Urticaria, fever | 1-72 hours | Stop drug; antihistamines |
| Late (Type III/IV) | Serum sickness, maculopapular rash, hemolytic anemia | >72 hours | Stop drug; steroids if severe |
- Cross-reactivity with cephalosporins: ~1-2% (older estimates of 10% were overestimates). Related to shared R1 side chain, not the beta-lactam ring. If true anaphylaxis to penicillin, avoid cephalosporins with similar side chains; carbapenems have ~1% cross-reactivity.
- Maculopapular rash with ampicillin/amoxicillin: ~5-10% of patients; up to 80-100% in patients with EBV mononucleosis or CLL. NOT a true allergic reaction - do NOT label as penicillin allergy. Due to immune complex deposition.
- Antibiotic allergy delabeling: Many patients labeled "penicillin allergic" are NOT truly allergic. Penicillin skin testing + graded challenge is the standard approach to delabel.
Other Adverse Effects
| Effect | Drug(s) | Notes |
|---|
| Diarrhea | Amoxicillin-clavulanate most common | Clavulanate causes GI upset; take with food |
| C. difficile colitis | All (any antibiotic) | Particularly with broad-spectrum agents |
| Neurotoxicity/seizures | High-dose IV Pen G | Especially in renal failure - can't clear drug fast enough |
| Hypokalemia | Piperacillin-tazo | Monitor electrolytes |
| Interstitial nephritis | Methicillin (major reason discontinued), nafcillin | Immune-mediated |
| Hepatotoxicity | Oxacillin | Transaminase elevation |
| Neutropenia | Nafcillin | With prolonged use |
| Jarisch-Herxheimer reaction | Penicillin G (syphilis) | Fever, chills, myalgias 2-8 hours after first dose; due to cytokine release from dying spirochetes; NOT allergy; managed with NSAIDs |
8. Contraindications
| Contraindication | Details |
|---|
| Prior severe penicillin allergy | Anaphylaxis, Stevens-Johnson syndrome - absolute contraindication to any penicillin |
| Renal failure (without dose adjustment) | Dose must be reduced for all renally cleared penicillins (exception: nafcillin) |
| High-dose Pen G in hypokalemia/hypernatremia | Large IV doses contain significant sodium - caution in heart failure, hypertension |
| Infectious mononucleosis | Avoid ampicillin/amoxicillin (causes severe rash) |
| MRSA infection | No penicillin is effective against MRSA |
9. Drug Interactions
| Interaction | Mechanism | Clinical significance |
|---|
| Probenecid | Blocks tubular secretion | Raises/prolongs penicillin levels - used therapeutically |
| Methotrexate | Penicillins reduce MTX renal clearance | Increased MTX toxicity - monitor |
| Warfarin | Altered gut flora, reduced vitamin K | Enhanced anticoagulation - monitor INR |
| Oral contraceptives | Disruption of enterohepatic cycling (theoretical, clinically minor) | Counsel patients |
| Aminoglycosides | Chemical inactivation if mixed in same IV line | Never mix in same syringe; synergistic if given separately |
| Bacteriostatic antibiotics | May antagonize penicillin's bactericidal action (theoretical) | Usually clinically insignificant |
10. Pregnancy and Special Populations
- Pregnancy: Penicillins are Category B - considered safest antibiotics in pregnancy. Used for GBS prophylaxis in labor (Pen G 5 million units IV load, then 2.5-3 million units IV q4h until delivery).
- Neonates: Dose by gestational age and postnatal age (different tables for PMA <34 weeks). Ampicillin + gentamicin is standard neonatal sepsis empiric therapy.
- Renal failure: Reduce dose/extend interval for all penicillins EXCEPT nafcillin. Rule of thumb: if CrCl <10 mL/min, give 1/4 to 1/3 of normal dose.
- Hepatic failure: Nafcillin requires dose adjustment (hepatic clearance); others are generally safe.
- Dialysis patients: Give after dialysis (penicillins are dialyzable).
11. Quick Reference - Drug of Choice Summary
| Infection | Preferred Penicillin | Dose / Duration |
|---|
| Streptococcal pharyngitis | Penicillin V PO or Amoxicillin PO | Pen V 500 mg QID x 10d or Amox 500 mg BID x 10d |
| Strep throat (single shot) | Benzathine Pen G IM | 1.2 million units IM x1 |
| Rheumatic fever prophylaxis | Benzathine Pen G IM | 1.2 million units IM q3-4 weeks |
| Syphilis (primary/secondary) | Benzathine Pen G IM | 2.4 million units IM x1 |
| Syphilis (neurosyphilis) | Penicillin G IV | 3-4 million units q4h x 10-14 days |
| Meningococcal meningitis | Penicillin G IV | 4 million units q4h x 7-10 days |
| Pneumococcal pneumonia (sensitive) | Penicillin G or Amoxicillin | Pen G 1-2 million units IV q4h or Amox 500 mg TID |
| Enterococcal endocarditis | Ampicillin IV + gentamicin | Ampicillin 2 g q4h x 4-6 weeks |
| Listeria meningitis | Ampicillin IV + gentamicin | Ampicillin 2 g q4h x 21 days |
| MSSA bacteremia/endocarditis | Nafcillin or Oxacillin IV | 2 g q4h x 4-6 weeks |
| MSSA cellulitis (outpatient) | Dicloxacillin PO | 500 mg q6h x 5-10 days |
| Strep pharyngitis + sinusitis | Amoxicillin-clavulanate | 875/125 mg BID x 5-7 days |
| Animal bites | Amoxicillin-clavulanate | 875/125 mg BID x 5-7 days |
| Aspiration pneumonia | Ampicillin-sulbactam IV | 3 g q6h x 7-10 days |
| Febrile neutropenia | Piperacillin-tazobactam IV | 4.5 g q6h until ANC recovery |
| Hospital-acquired pneumonia | Piperacillin-tazobactam IV | 4.5 g q8h extended infusion |
| Community-acquired UTI | Amoxicillin-clavulanate or Amoxicillin | 500 mg TID x 3-7 days (check local susceptibility) |
| H. pylori (triple therapy) | Amoxicillin + clarithromycin + PPI | Amox 1 g BID x 14 days |
| GBS prophylaxis in labor | Penicillin G IV | 5 million units load, then 2.5-3 million units q4h |
| Gas gangrene | Penicillin G IV + surgical debridement | 3-4 million units q4h x 10-14 days |
| Lyme disease (early) | Amoxicillin | 500 mg TID x 14-21 days |
| Otitis media | Amoxicillin high dose | 90 mg/kg/day BID x 10 days (children) |
12. How to Think About Penicillin Choice Clinically
Ask these 4 questions:
-
What organism am I treating?
- Strep/meningococcus/spirochete → Pen G or Pen V or Amoxicillin
- Staph (MSSA) → Nafcillin/Oxacillin (IV) or Dicloxacillin (oral)
- MRSA? → No penicillin works; use vancomycin/daptomycin
- Mixed gram-negative (non-Pseudomonal) → Ampicillin-sulbactam or Amox-clav
- Pseudomonas risk → Piperacillin-tazobactam
-
What site is infected (and what route can I use)?
- CNS/meningitis → High-dose IV Pen G (if sensitive organism) for CSF penetration
- Oral outpatient → Amoxicillin, Amox-clav, Pen V, Dicloxacillin
- Serious systemic → IV route required (Pen G, Nafcillin, Ampicillin, Pip-Tazo)
-
What is the local resistance pattern?
- Check antibiogram for local MSSA rate, ESBL rates, Pseudomonas susceptibility
- High-dose amoxicillin for Strep pneumo (overcomes intermediate resistance by achieving levels above MIC)
-
What are the patient's limitations?
- Renal failure → Nafcillin preferred; adjust others
- Pen allergy → Use azithromycin (strep throat), vancomycin (MSSA), fluoroquinolones (respiratory), or do penicillin allergy workup/delabeling
Sources: Goodman & Gilman's The Pharmacological Basis of Therapeutics, Katzung's Basic and Clinical Pharmacology 16th Ed., Jawetz Melnick & Adelberg's Medical Microbiology 28th Ed., The Harriet Lane Handbook 23rd Ed.